1. Internationalstudy: "multiphase IIIb of the effect of morbidity, Sibutramine  in overweight or obese individuals who present a risk of cardiovascular accident". Principal Investigator - SCOUT (Sibutramine Cardiovascular Outcome Trial), 2003-2009;(vezi articol)


2. International study: "multiphase IIIb, double-blind placebo-controlled with Olmesartan Medoxomil SE 866/44 on microalbuminuria prevention in patients with diabetes mellitus". Principal Investigator - Roadmap (Randomized Olmesartan and Diabetes Microalbuminuria Study prevention) 2003-2008, Sankyo Pharma;(vezi articol)

3. International study of multi-phase III, randomized, double-blind comparison of benfluorex versus pioglitazone in combination with sulfonil ureice administered orally in the treatment of diabetes mellitus type II - Principal Investigator - Mediator CL3-00780-148 - IRIS (Institute de Recherches Internationales Servier), 2006-2008; 

4. International Study: "multi phase IIIb, randomized double-blind to determine the efficacy and safety of treatment by adding a dose of 25 mg syr 322 versus pioglitazona dose modification in patients with diabetes mellitus type II, which presents an inadequate glucose control on metformin treatment and pioglitazone". Principal Investigator - Takeda 001-TL-004-OPI322, 2007-2009.

5. International study: "multi phase IIIb, randomized double-blind to determine the efficacy and safety pioglitazone and 322 patients with diabetes mellitus type II" principal investigator - Takeda 006-, 2007-2009 

6. International study: "multi-phase II, randomized double-blind to determine the effectiveness Roflumilast in patients with diabetes mellitus type II" - Principal Investigator - Study Altana, 2006-2007. 

7. International study: "multi-phase II, randomized double-blind evaluation of efficacy and safety management MGA031 (anti CD3 monoclonal antibody) without affinity for FCR in children and adults with diabetes mellitus type I recently discovered"- principal investigator - Macrogenics CP-01-MGA031 , 2006-2008. 

8. International study : "multi-phase II, randomized, multi-, double-blind placebo-controlled investigation of pharmacodinamics, safety, tolerance and pharmacokinetics of GLP1 analogues in patients with diabetes mellitus type II treated with metformin dose stable" - principal Investigator - Ro-5073031 analogues of GLP-1, BC 20688, 2006-2007. 

9. Multinational study: "multi-phase II, randomized double-blind evaluation of the safety and tolerability of administration Aliglitazar in patients with diabetes mellitus type II and heart failure NYHA class II compared with actos" - principal Investigator - 0728804 BC EN 20265 - Dual PPAR α/γ agonist, 2006-2007; 

10. International study: "multi-phase III, randomized, double blind, placebo controlled parallel groups to determine the efficacy, safety and tolerability Cetilistat obese patients" - principal investigator - 1218.16 - Boehringer Ingelheim, 2008. 

11. International study: "multiphase IIIb, double-blind placebo-controlled patients with diabetes mellitus type II treated with metformin dose Trial" - Principal Investigator stable phase III 2008-2009 - Toccata EFC10518 - Rimonabant. 

12. Noninternational study, multi-phase IV, which follows the algorithm for adjusting the dose of Lantus in patients with diabetes mellitus type II - Principal Investigator-Study ROLANDO, Sanofi Aventis, 2007-2008. 

13. Noninternational study, multi-phase IV, which supports the efficacy and safety management of Apidra in patients with diabetes type I or II - Principal Investigator-Odyssey Study, 2007-2008.

14. International study "multi-phase II, double blind, controlled parallel groups, 4 different doses of MP 513 attached on the patients with diabetes mellitus type II treated with metformin dose". Principal Investigator, Icon- Mitsubishi, 2009-2011. 

15. International study of multi-phase II, open label, randomized controlled parallel groups to determine the efficacy, safety and tolerability BIM 23 A 760 on acromegalic patients. Principal Investigator, 2010.

16. Double blind study, phase III,randomized, controlled parallel groups, active controlled, to determine the efficacy, safety and tolerability LCZ696 comparative with enalapril in patients with heart failure, Co-investigator, 2010.

17. International study, double blind, controlled parallel groups, to determine the efficacy valsartan/amlodipin 160/5 mg comparatif with  160 mg valsartan in monoterapy in patients with HTA, Co-investigator, 2010.

18. International study of multi-phase IIb AZD165D1020200009 in patients with diabetes mellitus type II treated with metformin dose stable, Astra-Zeneca, Principal Investigator, 2010.

19. Observational study DSE-OLM02-ROADMAP, observational Folow-up (OFU), Principal Investigator, 2010.

20. Double blind study, phase IIb with CI-004 in patients with diabetes mellitus type II, Astelas Pharma US, Principal Investigator, 2010.

21. International study phase IIb, randomized, placebo controlled to determine the efficacy, safety and tolerability MK-3102, MSD, Principal Investigator, 2011.

22. A randomised, double blind, placebo controlled, phase IIb study of LY2409021, I1R-MC-GLBG, in patients with type 2 diabetes mellitus, Eli Lilly, Principal Investigator, 2011.

23.    A randomised, double blind, placebo controlled, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetes mellitus patients after an acute coronary syndrome event, EFC11319-ELIXA,  Sanofi Aventis, Principal Investigator, 2011.

24.    A prospective, randomised, open-label comparison of a long-acting basal insulin analog LY2963016 to Lantus in combination with Type 1 Diabetes mellitus, protocol I4L-MC-ABEB,  Eli Lilly, Principal Investigator, 2011.

25. International follow-up study, after the investigational drug exposure in diabetic patients previously included in the REGULATE trial, protocol CL3-00780-150, IRIS – SERVIER PHARMA, Principal Investigator, 2011


26. A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformine, 2012 (EFC12261).

27. International study phase IV: "Newly Diagnosed or Treatment Naïve Adult Patients with T2DM who have Inadequate Glycemic Control with Diet and Exercise" 2014.

28.GW/DM1302- A randomised,double blind,placebo controlled,parallel group,dose-ranging study of GWP42004 ass add on to metformin in the treatment of particiopants with diabetes mellitus (2015)

29. CV181206- A 24 week international, multicenter, randomized, parallel group, double-blind trial to evaluate Metformin extended release monotherapy compared to metformin immediate release monotherapy in other subjects with type II diabetes who have inadequate glycemic control with diet and exercise (2013-2015)

30. MK8835-002 A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK8835/PF-04971729) compared with the Addition of Glimepiride in Subjects with Type 2 Diabetes Mellitus who have inadequate Glycemic control on Metformin (2014-2016)

31. MK8835-005 A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF—0497l 729) With Sitagliptin Compared With Ertuglitlozin Alone and Sitagliptin Alone, in the Treatment of Subjects With TZDM With Inadequate Glycemic Control on Metformin Monotherapy (2014-2016)

32. Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD) stadiu - recrutare pacienti -   https://clinicaltrials.gov/ct2/show/NCT02545049?term=17530&rank=2

33. Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD) stadiu - recrutare pacienti -  https://clinicaltrials.gov/ct2/show/study/NCT02540993?term=16244&rank=2#contacts